Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group) announced that it received accreditation from Great Place To Work®, the global management consulting firm that provides best-in-class data about the employee experience and establishes benchmarks for working conditions around the world.

"Sentynl Therapeutics is honored to be a Great Place To Work as part of Zydus Americas. This recognition is especially meaningful because it's earned through the opinions of employees themselves," said Matt Heck, President & Chief Executive Officer of Sentynl. "In partnership with Zydus, we are committed to building and maintaining a company culture that our employees are proud of, so we can achieve impact with integrity."

Zydus Americas had a 94% employee survey response rate, with an exceptional 90% saying that it is a great place to work, far higher than the average of 57% for typical U.S. companies.

Speaking on the recognition, Dr. Punit Patel, President & CEO of Zydus Americas, said, "At Zydus, we know that our dedicated employees drive our success, innovation and impact. It is crucial to ensure that our workforce feels supported and uplifted, and we are proud to be recognized for these efforts."

Great Place To Work is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. As part of Zydus Americas, Sentynl earned accreditation through the firm's two tools – the Trust Index© employee survey and the Culture Brief™ company questionnaire. The Trust Index measures individual employee experiences using five dimensions of high-trust company culture, credibility, respect, fairness, pride and sense of belonging, through 60 statements and two open-ended questions.